Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19.
J Thromb Thrombolysis
; 51(3): 657-662, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-871528
ABSTRACT
Coronavirus disease-2019 (COVID-19) is a rapidly evolving health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a novel disease entity and we are in a learning phase with regards to the pathogenesis, disease manifestations, and therapeutics. In addition to the primary lung injury, many patients especially the ones with moderate to severe COVID-19 display evidence of endothelial damage, complement activation, which leads to a pro-coagulable state. While there are still missing links in our understanding, the interplay of endothelium, complement system activation, and immune response to the SARS-CoV-2 virus is a surprisingly major factor in COVID-19 pathogenesis. One could envision COVID-19 becoming a novel hematological syndrome. This review is to discuss the available literature with regards to the involvement of the complement system, and coagulation cascade and their interaction with endothelium.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Endothelium, Vascular
/
Complement Activation
/
Thrombotic Microangiopathies
/
COVID-19
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Thromb Thrombolysis
Journal subject:
Vascular Diseases
Year:
2021
Document Type:
Article
Affiliation country:
S11239-020-02297-z
Similar
MEDLINE
...
LILACS
LIS